We are live on
!
Find out more
ABG
Ally Bridge Group Portfolio holdings
AUM
$124M
1-Year Est. Return
249.88%
This Fund
S&P 500
This Quarter
Est. Return
+9.5%
1 Year Est. Return
+249.88%
3 Year Est. Return
+942.29%
5 Year Est. Return
+671.08%
10 Year Est. Return
–
AUM
$168M
AUM Growth
-$12M
(-6.7%)
Cap. Flow
-$14M
Cap. Flow
% of AUM
-8.32%
Top 10 Holdings %
Top 10 Hldgs %
55.87%
Holding
32
New
10
Increased
1
Reduced
13
Closed
7
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Sarepta Therapeutics
SRPT
|
+$9.44M |
| 2 |
Legend Biotech
LEGN
|
+$9M |
| 3 |
ALMS
Alumis Inc
ALMS
|
+$8.23M |
| 4 |
DAWN
Day One Biopharmaceuticals
DAWN
|
+$7.84M |
| 5 |
Perspective Therapeutics
CATX
|
+$5.73M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
VRNA
Verona Pharma
VRNA
|
+$11.9M |
| 2 |
BPMC
Blueprint Medicines
BPMC
|
+$8.54M |
| 3 |
Dianthus Therapeutics
DNTH
|
+$6.51M |
| 4 |
Olema Pharmaceuticals
OLMA
|
+$6.33M |
| 5 |
LYRA
LYRA THERAPEUTICS INC
LYRA
|
+$6.24M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
26
Dianthus Therapeutics
DNTH
$5.73B
| – | – |
-216,968
| Closed | -$6.51M |
|
|
LYRA
27
DELISTED
LYRA THERAPEUTICS INC
LYRA
| – | – |
-20,075
| Closed | -$6.24M |
|
|
MRSN
28
DELISTED
Mersana Therapeutics
MRSN
| – | – |
-32,057
| Closed | -$3.59M |
|
|
29
Olema Pharmaceuticals
OLMA
$1.03B
| – | – |
-559,035
| Closed | -$6.33M |
|
|
RAPT
30
DELISTED
RAPT Therapeutics
RAPT
| – | – |
-52,500
| Closed | -$3.77M |
|
|
VRNA
31
DELISTED
Verona Pharma
VRNA
| – | – |
-736,738
| Closed | -$11.9M |
|
|
MRNS
32
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
| – | – |
-394,773
| Closed | -$3.57M |
|
Similar funds
MP
EWP
WFA
VWM
EI
TC
IFO
CRW
Ally Bridge Group's Q2 2024 Portfolio in Review
As of Q2 2024, Ally Bridge Group held 32 positions worth $168M, down 6.7% from $180M the previous quarter. Its ten largest holdings account for 56% of the portfolio.
Ally Bridge Group withdrew a net $14M in Q2 2024, closing 7 positions and reducing 13 holdings. Its most notable exit was Verona Pharma, an estimated $11.9M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 98% a quarter earlier.
Against the trend, Ally Bridge Group opened a new position in Sarepta Therapeutics worth $11.6M.
- Ally Bridge Group's largest Q2 2024 buy was Sarepta Therapeutics: 73,500 shares worth $11.6M.
- Ally Bridge Group added most to Context Therapeutics in Q2 2024, an estimated $2M increase.
- Ally Bridge Group's biggest Q2 2024 reduction was Blueprint Medicines, cutting an estimated $8.54M.
- Ally Bridge Group fully exited Verona Pharma in Q2 2024, selling an estimated $11.9M.
- Ally Bridge Group's ten largest holdings make up 56% of its $168M portfolio in Q2 2024.
- Ally Bridge Group opened 10 new positions and closed 7 in Q2 2024.
- Ally Bridge Group's portfolio value fell 6.7% quarter-over-quarter to $168M.
Based on Ally Bridge Group's 13F filing for Q2 2024, filed 14 Aug 2024.